Yes I hope that for pancreatic cancer patients sake that MultiTAA provides the efficacy needed for complete response.
Having said that, if it works that well in pancreatic cancer I don't believe we will get the maximum value of the stock. I see either a partnership with upfront cash/milestone payments/royalties for a straight up buyout in 2 years. Me Personally, I hope management don't sell as that would be a disservice to shareholders.